Roles for aberrant CXCR3 signaling in basal cell carcinoma: A case for dual activity

American Journal of Pathology

Volumn 176, Issue 5, 2010, Pages 2088-2091

  Yu, Yanlin ^a   Merlino, Glenn ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

ANTIANGIOGENIC ACTIVITY; BASAL CELL CARCINOMA; CANCER CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; DOWN REGULATION; ENZYME REGULATION; HETEROZYGOSITY LOSS; IMMUNE RESPONSE; IN VIVO STUDY; KERATINOCYTE; MICROENVIRONMENT; NOTE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 77952078689     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.091284     Document Type: Note

References (20)

1. Hanahan D, Weinberg R: The hallmarks of cancer. Cell 2000, 100:57-70
2. Yu Y, Merlino G: Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model. Cancer Res 2002, 62:2951-2956 (Pubitemid 34525784)
3. Lo B, Yu M, Zloty D, Cowan B, Shapiro J, McElwee KJ: CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. Am J Pathol 2010, 176:2435-2446
4. Liu L, Callahan MK, Huang D, Ransohoff RM: Chemokine receptor CXCR3: an unexpected enigma. Curr Top Dev Biol 2005, 68:139-181
5. Ehlert JE, Addison CA, Burdick MD, Kunkel SL, Strieter RM: Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J Immunol 2003, 173:6233-16230
6. Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A: CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. J Clin Pathol 2007, 60:596-599
7. Ma X, Norsworthy K, Kundu N, Rodgers WH, Gimotty PA, Goloubeva O, Lipsky M, Li Y, Holt D, Fulton A: CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 2009, 8:390-398
8. Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, Witz IP, Ben-Baruch A: CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 2007;67: 3396-13305
9. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, Marra F, Romagnani S, Serio M, Romagnani P: An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10. Mig, and I-TAC, and acts as functional receptor for platelet factor 3. J Exp Med 2003, 197:1537-1539
10. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, Uguccioni M, Galli G, Cosmi L, Maurenzig L, Baggiolini M, Maggi E, Romagnani S, Serio M: Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. J Clin Invest 2001, 107:53-63
11. Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S: Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-335 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res 2006, 66:9509-9518 (Pubitemid 44623649)
12. Moser B, Loetscher P: Lymphocyte traffic control by chemokines. Nat Immunol 2001, 2:123-128
13. Shahabuddin S, Ji R, Wang P, Brailoiu E, Dun N, Yang Y, Aksoy MO, Kelsen SG: CXCR3 chemokine receptor-induced chemotaxis in human airway epithelial cells: role of p38 MAPK and PI3K signaling pathways. Am J Physiol Cell Physiol 2006, 291:C33-C39
14. Maru SV, Holloway KA, Flynn G, Lancashire CL, Loughlin AJ, Male DK, Romero IA: Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation. J Neuroimmunol 2008, 199:35-45
15. Walser TC, Rifat S, Ma X, Kundu N, Ward C, Goloubeva O, Johnson MG, Medina JC, Collins TL, Fulton AM: Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 2006, 66:7701-7707
16. Goldberg-Bittman L, Neumark E, Sagi-Assif O, Azenshtein E, Meshel T, Witz IP, Ben-Baruch A: The expression of the chemokine receptor CXCR3 and its ligand. CXCL10, in human breast adenocarcinoma cell lines Immunol Lett 2003, 92:171-178
17. Robledo MM, Bartolome RA, Longo N, Rodríguez-Frade JM, Mellado M, Longo I, van Muijen GN, Sánchez-Mateos P, Teixidó J: Expression of functional chemokine receptors CXCR3 and CXCR3 on human melanoma cells. J Biol Chem 2001, 276:35098-35105
18. Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, Vorechovsky I, Holmberg E, Unden AB, Gillies S, Negus K, Smyth I, Pressman C, Leffell DJ, Gerrard B, Goldstein AM, Dean M, Toftgard R, Chenevix-Trench G, Wainwright B, Bale AE: Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996, 85:831-851
19. Fan H, Oro AE, Scott MP, Khavari PA: Induction of basal cell carcinoma features in transgenic human skin expressing Sonic Hedgehog. Nat Med 1997, 3:788-792
20. Dahmane N, Lee J, Robins P, Heller P, Ruiz i, Altaba A: Activation of the transcription factor Gli1 and the Sonic hedgehog signalling pathway in skin tumours. Nature 1997, 389:876-881